Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABO2202
- Development stage
- Unknown
- Lead developer
- Abogen Bioscience
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal
01
Overview
ABO2202 is an investigational mRNA-based therapeutic designed to encode a bispecific antibody targeting Epithelial Cell Adhesion Molecule (EpCAM) and CD3. Developed by Ruijin Hospital at Shanghai Jiao Tong University School of Medicine, the drug is formulated as a nanoparticle for intraperitoneal administration. Its mechanism involves the in vivo production of bispecific antibodies that bridge EpCAM-expressing tumor cells (common in gastric cancer and peritoneal metastases) with CD3-positive T cells, thereby inducing T-cell mediated cytotoxicity against the cancer cells. It is currently being evaluated in clinical trials for advanced gastric cancer with peritoneal metastasis and malignant ascites, often in combination with systemic chemotherapy.
- Other names
- EpCAM/CD3 bispecific antibody mRNAABO2202 mRNA nanoparticleABO-2202 mRNA nanoparticleABO 2202 mRNA nanoparticle
02
Targets
CD3 (T-cell surface glycoprotein CD3)EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on ABO2202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABO2202.